source
- Government policies strain funding and operations for small biotech firmsCassel Salpeter's latest healthcare investment report says that recent government actions, including FDA staff reductions, slower federal research grants and higher tariffs, are creating a tough fu…
- AbbVie inks up to $2.5 billion deal with Disco to pursue bispecific cancer therapeuticsAbbVie announced a collaboration with German biotech Disco Pharmaceuticals that could be worth up to $2.5 billion. The agreement provides a $40 million upfront payment, with the balance linked to…